Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford Vaccine Group director and Professor of Paediatric Infection at the Department of Paediatrics, Professor Andrew Pollard, discusses the work of the Oxford Vaccine Group

In this issue, we talk to Professor Andrew Pollard, Professor of Paediatric Infection and Immunity in the Department of Paediatrics, and Director of the Oxford Vaccine Group (OVG).

Professor Andrew Pollard

Tell us about the Oxford Vaccine Group
The Oxford Vaccine Group (OVG) is a multi-disciplinary team working on the design, development and evaluation of vaccines to improve human health through the prevention of serious infectious disease. Celebrating our 20th anniversary in 2014, a major focus of our work has been developing and studying vaccines against important pathogenic bacteria that cause serious infections, such as meningitis, pneumonia and typhoid, in infants and children. Over the past decade, the group has grown to more than 70 staff in the UK and Nepal, including clinical staff (nurses and research fellows), clinical trial support staff and laboratory scientists.

 

Why is the work of the OVG so important? 
Vaccines are a key component of global public health policy and are particularly important in the defence of the health of young children. Despite the challenges of so doing, new and improved vaccines must be evaluated in the target population of infants and young children prior to licensure. Since 2001, we have enrolled over 10,000 children and young people into a number of clinical trials, including phase IV studies of a meningitis C vaccine and a pneumococcal conjugate vaccine; a phase II study of a new pneumococcal vaccine for infants; phase II and III studies of quadrivalent meningococcal vaccines and group B meningococcal vaccines; phase II studies of a preschool vaccine; evaluation of a novel avian and swine influenza vaccines in adults and children; and study of different schedules for immunisation of the elderly against pneumococcal infection.

This research underpins half of the vaccines in the NHS childhood immunisation schedule and is cited in the vaccine policies of many countries around the world. We have a substantial portfolio of research with  over 200 publications in the last ten years and have attracted over £7M in grant funding since January 2013. Additionally, ten DPhil students have graduated at OVG in the past five years.

 

As well as conducting clinical trials, what other research is the OVG involved in? 
We undertake epidemiological studies, including evaluation of carriage of Haemophilus influenzae type b and Streptococcus pneumoniae in childhood in the UK and Nepal, and surveillance of invasive bacterial infections in children admitted to Patan hospital in Kathmandu, where we are now assessing the impact of the new pneumonia vaccine which is being implemented there in 2014.


In the laboratory we drive projects using our unique access to our clinical trials samples evaluating the developing immune system in the infant and child. The group has specifically focused on the development of B cell memory after immunization with glycoconjugate vaccines and has found correlations between the generation of memory during priming and the persistence of the immune response. A major programme is focussed on the development of novel serogroup B meningococcal vaccines from preclinical studies through to clinical trials. In a ground-breaking study, the group are developing a human paratyphoid model for the evaluation of paratyphoid vaccines, building on recent work with typhoid. A bank of DNA has been collected from children enrolled in vaccine trials and studies of the genetic control of the immune response following immunisation are currently underway.

 

OVG - Lab What’s one of the more interesting techniques you are using? 

We are studying whether typhoid and paratyphoid vaccines work through use of a human challenge model. By deliberately infecting vaccinated volunteers with the bacteria, we can see whether they are protected and then study the mechanisms of protection.

 What's a typical day like in the OVG?

Mad!!

 

OVG - Freezer Small

Links:

Oxford Vaccine Group (OVG)

 

The Oxford Vaccine Group would like to acknowledge and thank its funders:  Wellcome Trust, MRC, NIHR EME and HTA programme, Bill and Melinda Gates Foundation, Action Medical Research, Meningitis Research Foundation, Meningitis UK, Global Alliance for Vaccines and Immunisation, World Health Organisation, and vaccine manufacturers.

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.